Immuneering Corporation
- Biotech or pharma, therapeutic R&D
Immuneering is a clinical-stage oncology company developing medicines for patient with RAS/RAF mutations. Lead program is in phase 2A for pancreatic, melanoma, and NSCLC. Positive top line results disclosed - 43% and 50% ORR in combination with mGnP and mFFX, respectively in 1L pancreatic cancer.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}